| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268390 Inhibiting stenosis following vascular trauma or disease in a mammalian host. |
| 07/31/2001 | US6268389 Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists |
| 07/31/2001 | US6268388 Method for preventing or treating erectile dysfunction by administering an endothelin antagonist |
| 07/31/2001 | US6268387 Inhibitors of the enzyme 15-lipoxygenase and are inhibitors of monocyte chemotaxis. |
| 07/31/2001 | US6268386 Nicotine beverage |
| 07/31/2001 | US6268385 Dry blend pharmaceutical formulations |
| 07/31/2001 | US6268383 Containing a phenanthrene ring; e.g., desbutylhalofantrine. |
| 07/31/2001 | US6268382 Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268378 Integrin receptor antagonists |
| 07/31/2001 | US6268377 Method for treating androgen-related conditions |
| 07/31/2001 | US6268376 Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones |
| 07/31/2001 | US6268375 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition |
| 07/31/2001 | US6268374 Uracil reductase inactivators |
| 07/31/2001 | US6268372 Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
| 07/31/2001 | US6268369 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 07/31/2001 | US6268368 Antidepressants |
| 07/31/2001 | US6268367 Piperazine derivatives for treating bone deficit conditions |
| 07/31/2001 | US6268365 Src family SH2 domain inhibitors |
| 07/31/2001 | US6268363 Antitumor |
| 07/31/2001 | US6268362 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 07/31/2001 | US6268361 Estrogen dependent disorders including cancer, enodmetriosis, etc |
| 07/31/2001 | US6268359 Preventives or remedies for vision disorders |
| 07/31/2001 | US6268358 Compounds for the treatment of Alzheimer's disease |
| 07/31/2001 | US6268355 Stable aspirin-containing preparations for external use |
| 07/31/2001 | US6268354 Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| 07/31/2001 | US6268352 Promoters of neural regeneration |
| 07/31/2001 | US6268351 Methods for inducing proliferation in auditory receptor epithelium |
| 07/31/2001 | US6268347 Alleviating neuropathic pain |
| 07/31/2001 | US6268333 Blend with 1,3-dimethoxy-5-methylbenzene; stimulative component is a jasmine formulation. |
| 07/31/2001 | US6268207 Resolution of enantiomers from a mixture of (1r,2s)/(1s,2s)-1-amino-2-vinylcyclopropyl carboxylic acid methyl ester comprising the step of treating said mixture with an esterase to obtain the corresponding (1r,2s) enantiomer |
| 07/31/2001 | US6268186 By recovering compounds such as lovastatin from a fermentation broth by purifying with an adsorbent resin, extraction using toluene, lactonization, if necessary and washing in toluene with water before isolation |
| 07/31/2001 | US6268182 Enzymatically degrading starch in combination with glycosyltransferase to act on starch having at least one phosphate group per molecule; phosphorylated saccharide reacts with minerals and prevents insolubization of minerals |
| 07/31/2001 | US6268163 Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| 07/31/2001 | US6268156 Testing patients being treated with cimetidine for colorectal cancer for sialyl lewis x antigen |
| 07/31/2001 | US6268151 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/31/2001 | US6268138 Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs |
| 07/31/2001 | US6268126 Administering polymer with aliphatic spacer to treat infection |
| 07/31/2001 | US6268120 Isoalloxazine derivatives to neutralize biological contaminants |
| 07/31/2001 | US6268011 Mixture of soybean protein and soybean fiber |
| 07/31/2001 | US6267995 Isolated composition obtained by extracting lepidium meyenii roots with aqueous solvent, substantially free of cellulose, comprising benzyl isothiocyanate, lepidium sterol component, lepidium fatty acid component, and macamide component |
| 07/31/2001 | US6267994 Use of extract of cimicifuga racemosa |
| 07/31/2001 | US6267992 Administering metabolite of salviae miltiorrhizac radix herb to diabetic individual to treat diabetic nephropathy |
| 07/31/2001 | US6267990 Preparation comprising initial dose of ace inhibitor optionally including excipient, first delayed-release pellet, in which active ingredient and optional excipient are covered with coating, second coated delayed-release pellet |
| 07/31/2001 | US6267986 Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine |
| 07/31/2001 | US6267982 Estradiol dissolved in (meth)acrylate copolymer by drying and present in at least three times saturation solubility concentration measured at 95% relative air humidity, enclosed in moisture-tight package with low humidity air |
| 07/31/2001 | US6267980 Dosage forms and uses |
| 07/31/2001 | US6267977 Delivery of hydroxy carboxylic acids |
| 07/31/2001 | US6267973 Ectoin and ectoin derivatives as moisturizers in cosmetics |
| 07/31/2001 | US6267972 Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists |
| 07/31/2001 | US6267971 Use of cinnamic acid or of its derivatives in a cosmetic firming composition |
| 07/31/2001 | US6267952 Lipase inhibiting polymers |
| 07/31/2001 | US6267948 Administering to mammalian skin, hair, wool or fur dermatological formulation containing melanogenesis stimulating agent which stimulates melanogenesis in melanocytes and hydroxy acid to enhance melanogenesis |
| 07/31/2001 | US6267945 Farnesol-related calcium channel blockers |
| 07/31/2001 | US6267310 Process for separating particles of cohesive material according to size |
| 07/31/2001 | CA2332687A1 Use of prostaglandin (pge2) receptor 4 (ep4) selective agonists for the treatment of acute and chronic renal failure |
| 07/31/2001 | CA2282890C Therapeutic heterocyclic compounds |
| 07/31/2001 | CA2218663C Benzisoxazole and indazole derivatives as antipsychotic agents |
| 07/31/2001 | CA2214713C Topical antimicrobial agents |
| 07/31/2001 | CA2208639C Camptothecin derivatives and its manufacturing method |
| 07/31/2001 | CA2159555C Use of a chlorine canal associated agonist material for the treatment of wrinkles |
| 07/31/2001 | CA2121144C Oligonucleotides having chiral phosphorus linkages |
| 07/31/2001 | CA2072945C Pyrimidine derivatives |
| 07/31/2001 | CA2068763C Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| 07/31/2001 | CA2059305C Hexa-cyclic compound |
| 07/31/2001 | CA2041240C Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| 07/31/2001 | CA2035951C Bilobalide derivatives, their applications and formulations containing them |
| 07/31/2001 | CA2023944C Use of phospholipid derivatives as antiviral pharmaceutical and new phospholipids |
| 07/31/2001 | CA1341278C Combination of pyrimidine derivatives and retinoids in separate components to induce and stimulate hair growth and reduce hair loss |
| 07/31/2001 | CA1341276C Hyaluronic acid esters and salts |
| 07/29/2001 | CA2325930A1 A medicament for prevention and treatment of sexual dysfunction |
| 07/26/2001 | WO2005053669A1 Use of omega-3 polyunsaturated fatty acids for sleep apnoea |
| 07/26/2001 | WO2001053541A1 Antisense modulation of caspase 8 expression |
| 07/26/2001 | WO2001053540A1 Antisense modulation of pepck-cytosolic expression |
| 07/26/2001 | WO2001053528A1 Antisense inhibition of ptp1b expression |
| 07/26/2001 | WO2001053506A2 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | WO2001053505A2 Herpes virus strains for gene therapy |
| 07/26/2001 | WO2001053493A2 Human kinase protein and polynucleotides encoding the same |
| 07/26/2001 | WO2001053490A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom |
| 07/26/2001 | WO2001053489A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | WO2001053486A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | WO2001053482A1 VITAMIN D3-RESPONSE SEQUENCE LOCATED IN THE 5'-UPSTREAM OF p27/KiP1 GENE AND METHOD FOR SCREENING DRUG BY USING THE SEQUENCE |
| 07/26/2001 | WO2001053477A1 Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
| 07/26/2001 | WO2001053444A1 Antimicrobial compositions |
| 07/26/2001 | WO2001053351A2 Apoptin bindendes protein |
| 07/26/2001 | WO2001053346A1 Human cystine knot polypeptide |
| 07/26/2001 | WO2001053344A2 Chondromodulin-i related peptide |
| 07/26/2001 | WO2001053321A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053314A1 Antisense modulation of daxx expression |
| 07/26/2001 | WO2001053313A1 Antisense modulation of smad7 expression |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053310A1 Antisense modulation of caspase 3 expression |
| 07/26/2001 | WO2001053305A1 Processes for the preparation of carbapenem derivatives |
| 07/26/2001 | WO2001053299A1 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| 07/26/2001 | WO2001053297A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | WO2001053295A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 07/26/2001 | WO2001053294A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| 07/26/2001 | WO2001053293A1 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |